Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 11
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA; COVID-OUT Trial Team. Bramante CT, et al. N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662. N Engl J Med. 2022. PMID: 36070710 Free PMC article. Clinical Trial.
BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS: In this phase 3, dou …
BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensi …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. Wen W, et al. Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936. Ann Med. 2022. PMID: 35118917 Free PMC article.
BACKGROUND: The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a s …
BACKGROUND: The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have b …
Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis.
Deng J, Moskalyk M, Zuo QK, Garcia C, Abbas U, Ramaraju HB, Rayner D, Park YJ, Heybati K, Zhou F, Lohit S. Deng J, et al. Rev Med Virol. 2024 Jan;34(1):e2501. doi: 10.1002/rmv.2501. Epub 2023 Dec 26. Rev Med Virol. 2024. PMID: 38148036 Review.
This systematic review and meta-analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of fluvoxamine for the outpatient management of COVID-19. We conducted this review in accordance with the PRISMA 2020 guid …
This systematic review and meta-analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of …
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR; COVID-OUT Study Team. Bramante CT, et al. Lancet Infect Dis. 2023 Oct;23(10):1119-1129. doi: 10.1016/S1473-3099(23)00299-2. Epub 2023 Jun 8. Lancet Infect Dis. 2023. PMID: 37302406 Clinical Trial.
We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. METHODS: We conducted a decentralised, randomised, quadruple …
We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SAR …
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, de Souza Campos VH, Ferreira TS, Quirino Dos Santos CV, Ribeiro Nogueira AM, Figueiredo Guimaraes Almeida AP, Cançado Monteiro Savassi L, de Figueiredo Neto AD, Bitarães C, Cruz Milagres A, Diniz Callegari E, Campos Simplicio MI, Barra Ribeiro L, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Guyatt GH, Rayner CR, Boulware DR, Ezer N, Lee TC, McDonald EG, Bafadhel M, Butler C, Rodrigues Silva J, Dybul M, Mills EJ; TOGETHER Investigators. Reis G, et al. Ann Intern Med. 2023 May;176(5):667-675. doi: 10.7326/M22-3305. Epub 2023 Apr 18. Ann Intern Med. 2023. PMID: 37068273 Free PMC article. Clinical Trial.
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. ...MEASUREMENTS: The primary outcome was a composite of emergency setting retent …
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease …
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, Tu YK, Yang SN, Hsu TW, Yeh TC, Liang CS. Yu CL, et al. Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088. Int J Environ Res Public Health. 2023. PMID: 36901099 Free PMC article. Review.
Preliminary meta-analyses suggested that fluvoxamine was effective in treating COVID-19 infection. However, the reliability of this evidence has not yet been examined. ...The role of fluvoxamine as a COVID-19 treatment cannot be justified …
Preliminary meta-analyses suggested that fluvoxamine was effective in treating COVID-19 infection. However, the reliabi …
Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.
Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Lu LC, et al. J Infect Public Health. 2022 Nov;15(11):1259-1264. doi: 10.1016/j.jiph.2022.10.010. Epub 2022 Oct 13. J Infect Public Health. 2022. PMID: 36272390 Free PMC article.
OBJECTIVES: This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID-19. ...CONCLUSION: Fluvoxamine can be safely used in nonhospitalized patients with COVID-19 and can reduce the hos …
OBJECTIVES: This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID- …
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
Farahani RH, Ajam A, Naeini AR. Farahani RH, et al. BMC Infect Dis. 2023 Mar 31;23(1):197. doi: 10.1186/s12879-023-08172-5. BMC Infect Dis. 2023. PMID: 37003990 Free PMC article. Clinical Trial.
Therefore, we aimed to evaluate fluvoxamine's effect on PCS neuropsychiatric symptoms. METHOD: In this double-blind randomized clinical trial, we included confirmed mild to moderate COVID-19 outpatients using polymerase chain reaction (PCR) by an infectious d …
Therefore, we aimed to evaluate fluvoxamine's effect on PCS neuropsychiatric symptoms. METHOD: In this double-blind randomized clinic …
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.
Lee TC, Vigod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ, Reiersen AM, McDonald EG. Lee TC, et al. JAMA Netw Open. 2022 Apr 1;5(4):e226269. doi: 10.1001/jamanetworkopen.2022.6269. JAMA Netw Open. 2022. PMID: 35385087 Free PMC article.
OBJECTIVE: To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19. DATA SOURCES: World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov. …
OBJECTIVE: To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient managemen …
Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
Bhuta S, Khokher W, Kesireddy N, Iftikhar S, Beran A, Mhanna M, Patel NJ, Patel M, Burmeister C, Assaly R. Bhuta S, et al. Am J Ther. 2022 May-Jun 01;29(3):e298-e304. doi: 10.1097/MJT.0000000000001496. Epub 2022 Mar 31. Am J Ther. 2022. PMID: 35383578
BACKGROUND: Recent clinical trials have investigated the use of fluvoxamine in preventing clinical deterioration in nonhospitalized patients with acute COVID-19 infection via stimulation of sigma-1 receptors, which regulates cytokine production and functional …
BACKGROUND: Recent clinical trials have investigated the use of fluvoxamine in preventing clinical deterioration in nonhospitalized p …
24 results